Marie-France
Tschudin
Director of AXA
Swiss nationality
Mandate
Appointed on April 23, 2024 - Term expires at the 2027 Shareholders’ Meeting
First appointment on June 30, 2020
Member of the AXA Compensation, Governance & Sustainability Committee
Expertise and experience
Marie‑France Tschudin graduated with a Master of Business Administration (MBA) from IMD business school in Switzerland, and a Bachelor of Science from Georgetown University in the United States. Before joining Novartis, Marie‑France Tschudin spent 10 years at Celgene International in a variety of leadership positions across Europe. She joined Novartis in 2017 as Europe Region Head of Novartis Pharmaceuticals. From March to June 2019, she was President of Advanced Accelerator Applications, a Novartis company. In June 2019, she became President of Novartis Pharmaceuticals. In April 2022, Marie‑France Tschudin became President, Innovative Medicines International & Chief Commercial Officer of Novartis Pharma AG (Switzerland) and a member of the Executive Committee of Novartis (Switzerland) until September 2023, when she left the Novartis group.
Mandate held within the AXA Group
- Director: AXA
Mandate held outside the AXA Group
- Chair: SFNV (Swiss Food and Nutrition Valley) (Switzerland) (not‑for‑profit association)
- Director: Catalent, Inc (United States), IMD Foundation (Switzerland), Mars, Inc (United States)
Mandate held during the last five years
- President, Innovative Medicines International & Chief Commercial Officer: Novartis Pharma AG (Switzerland)
- President: Novartis Pharmaceuticals (Switzerland)
- Director: European Federation of Pharmaceutical Industries and Associations (EFPIA) (Belgium)